Akram Ghantous
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Akram Ghantous has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Shirdel
Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Ali Bazarbachi
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
1 shared publication - Ardeshir Ghavamzadeh
Tehran University of Medical Sciences
1 shared publication - Fadwa Berri
Department of Biology, Faculty of Sciences, Lebanese University, Hadath, Lebanon
1 shared publication - Ghada Kchour
Department of Biology, Faculty of Sciences, Lebanese University, Hadath, Lebanon
1 shared publication - Hiba El Hajj
Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
1 shared publication
Latest Publications
- Open Access
- 20 August 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 91
The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma
HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN.
- 20 August 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 91
Open AccessThe combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma
HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN.